The Romanian Competition Council fined Eli Lilly, a global pharmaceutical company, and its three Romanian distributors a total of e22 million for illegal market allocation and bid rigging in relation to certain diabetes drugs. The Competition Council also sanctioned the Ministry of Health for its failure to organise annual national tenders for diabetes drugs; the Council considered that this failure violated Romanian laws that prohibit public authorities from restricting competition. Eli Lilly and its distributors have appealed the fine before the Bucharest Court of Appeals.